Oxford Biomedica PLC Director Dealings (5891R)
September 22 2017 - 7:36AM
UK Regulatory
TIDMOXB
RNS Number : 5891R
Oxford Biomedica PLC
22 September 2017
Director Dealings / Market Share Purchase
Oxford, UK - 22 September 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the
Group, on Friday 22 September 2017 acquired ordinary shares in the
Group as set out below under the market share purchase agreement
outlined in the Group's announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr
Tallarigo's fees as Chairman, after tax, are to be used to purchase
shares in Oxford BioMedica PLC on a monthly basis at the prevailing
market price.
Interest after
purchase
----------- --------- ---------- ---------------- ----------------------------
Director Title Price Number of Number % of total
/ PDMR per share Ordinary Shares of Ordinary issued
(p) acquired Shares share capital
----------- --------- ---------- ---------------- ------------ --------------
Dr Lorenzo
Tallarigo Chairman 8.9p 29,685 2,082,425 0.07%
----------- --------- ---------- ---------------- ------------ --------------
The issued share capital of the Group is 3,106,253,317 ordinary
1p shares.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Stuart Paynter, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Philippa Gardner/Laura
Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
280 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHFMGZLMZKGNZM
(END) Dow Jones Newswires
September 22, 2017 07:36 ET (11:36 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024